Molecular Profile | MAP2K1 F53L |
Therapy | Cetuximab + Trametinib |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
Create By | spatt |
Update By | spatt |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | MAP2K1 F53L | colorectal cancer | sensitive | Cetuximab + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring MAP2K1 F53L in culture (PMID: 28179366). | 28179366 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(28179366) | Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations. | Full reference... |